**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 53539

**Manuscript Type:** REVIEW

**review of primary sclerosing cholangitis with increased IgG4 levels**

Manganis CD *et al*. PSC and high IgG4

Charis D Manganis, Roger W Chapman, Emma L Culver

**Charis D Manganis, Roger W Chapman, Emma L Culver,** Translational Gastroenterology Unit and Oxford NIHR Biomedical Research Centre, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom

**Author contributions:** Manganis CD and Culver EL performed the literature review and drafted the original manuscript; Chapman RW and Culver EL were responsible for conception and design of the study, critical revision and editing of the manuscript; all authors approved the final manuscript.

**supported by** the National Institute of Health Research Biomedical Research Centre, based at Oxford University Hospitals Trust; Oxfordshire Health Service Research Committee as part of Oxford Hospitals Charity, Oxford.

**Corresponding author: Emma L Culver, BSc, MBChB, DPhil, Doctor, Senior Lecturer, MRCP Gastro, Consultant Hepatologist**,Translational Gastroenterology Unit and Oxford NIHR Biomedical Research Centre, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU, United Kingdom. emma.culver@nhs.net

**Received:** December 23, 2019

**Revised:** April7, 2020

**Accepted:** June 5, 2020

**Published online:** June 21, 2020

**Abstract**

Primary sclerosing cholangitis (PSC) is a chronic progressive liver disease. Sub-types of PSC have been described, most recently PSC with elevated serum and/or tissue IgG4 subclass. We aim to summarise the clinical phenotype, disease associations, differential diagnosis, response to therapy and pathogenic mechanisms underlying PSC-high IgG4 subtype. We reviewed Pubmed, Medline and Embase with the search terms “primary sclerosing cholangitis”, “IgG4”, and “IgG4-related sclerosing cholangitis (IgG4-SC)”. Elevated serum IgG4 are found in up-to one-quarter, and abundant IgG4-plasma cell infiltrates in the liver and bile ducts are found in up-to one-fifth of PSC patients. This group have a distinct clinical phenotype, with some studies reporting a more aggressive course of liver and associated inflammatory bowel disease, compared to PSC-normal IgG4 and the disease mimic IgG4-SC. Distinguishing PSC-high IgG4 from IgG4-SC remains challenging, requiring careful assessment of clinical features, organ involvement and tissue morphology. Calculation of serum IgG4:IgG1 ratios and use of a novel IgG4:IgG RNA ratio have been reported to have excellent specificity to distinguish IgG4-SC and PSC-high IgG4 but require validation in larger cohorts. A role for corticosteroid therapy in PSC-high IgG4 remains unanswered, with concerns of increased toxicity and lack of outcome data. The immunological drivers underlying prominent IgG4 antibodies in PSC are incompletely defined. An association with PSC-high IgG4 and HLA class-II haplotypes (B\*07, DRB1\*15), T-helper2 and T-regulatory cytokines (IL4, IL10, IL13) and chemokines (CCL1, CCR8) have been described. PSC-high IgG4 have a distinct clinical phenotype and need careful discrimination from IgG4-SC, although response to immunosuppressive treatments and long-term outcome remains unresolved. The presence of IgG4 likely represents chronic activation to persistent antigenic exposure in genetically predisposed individuals.

**Key words:** Primary sclerosing cholangitis; IgG4; IgG4-related disease; IgG4-related sclerosing cholangitis

**Citation:** Manganis CD, Chapman RW, Culver EL. review of primary sclerosing cholangitis with increased IgG4 levels. *World J Gastroenterol* 2020; 26(23): 3126-3144

**URL:** https://www.wjgnet.com/1007-9327/full/v26/i23/3126.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v26.i23.3126

**Core tip:** Elevated serum IgG4 titres and/or abundant IgG4-positive plasma cell infiltrates in the liver and bile ducts are present in up-to one-quarter of patients with primary sclerosing cholangitis (PSC). It should be distinguished from IgG4-related sclerosing cholangitis. PSC with high IgG4 have a different clinical phenotype to those with normal IgG4, with higher bilirubin and alkaline phosphatase, higher PSC Mayo Risk Score, more advanced liver disease, shorter time to liver transplantation, more aggressive colitis and shorter time to colectomy. Corticosteroids may provide biochemical improvement but rarely results in cholangiographic resolution. Concerns include steroid toxicity, infection and disease progression in those with advanced cirrhosis.

**INTRODUCTION**

Primary sclerosing cholangitis (PSC) is a chronic progressive disease characterised by fibrosis and strictures of intra-hepatic and extra-hepatic bile ducts, leading to cirrhosis, liver failure and eventual death[1]. It is classified as a rare condition, affecting less than 200000 individuals in the United States and 250000 individuals across the European Union. However, its incidence is rising, which has been linked to changing environmental exposures[2]. There is a strong association with inflammatory bowel disease (IBD), particularly ulcerative colitis (UC), present in 80% of patients[3,4]. Co-existent autoimmune conditions have been reported in up to 25%[5]. PSC is considered a pre-malignant condition, with an increased risk of hepatobiliary and colorectal carcinomas[6]. Currently, there is no medical treatment that improves survival, with liver transplantation the only option for cure[7].

Sub-types of PSC have been described, including classical large-duct PSC, small-duct PSC, and "overlap syndrome" with autoimmune hepatitis[8]. More recently, a subset of patients with PSC and high immunoglobulin G subclass 4 (IgG4) levels has been identified. Early evidence suggested that patients with PSC and high IgG4 levels may have a distinct clinical phenotype. Such patients need to be carefully distinguished from those with IgG4-related sclerosing cholangitis (IgG4-SC), the biliary component of multi-systemic IgG4-related disease.

In this review, we describe the diagnostic pathway, disease phenotype and associations, response to therapy and putative pathogenic mechanisms underlying PSC with high IgG4 levels. We propose that PSC can be clinically sub-classified by serum IgG4 levels, based **on review of the literature, the evolution of clinical trial design in PSC to include serum IgG4 levels, and current clinical practice to risk stratify in tertiary high-volume centres diagnosing and managing patients with PSC.**

**LITERATURE SEARCH STRATEGY**

We searched Pubmed, Medline and Embase for all articles with the search terms “primary sclerosing cholangitis”, “IgG4”, and “IgG4-related sclerosing cholangitis”: 611 publications met the search criteria (536 in English language). Of these, 122 were review articles and 414 were original articles including case reports, case series, clinical cohort studies and clinical trials. We screened all abstracts and identified 108 articles with full text available relevant to this review; 36 of these specifically addressed primary sclerosing cholangitis and IgG4 levels. The abstracts and full text of relevant articles were independently assessed by two authors (EC and CM). A decision tree to reflect the literature search strategy is shown in Figure 1.

**PREVALENCE OF PSC WITH HIGH IGG4 LEVELS**

Early reports in the 1990’s describe patients with PSC-like biliary strictures and pancreatic disease, which was responsive to corticosteroid therapy[9-14]. In 2001, patients with biliary disease and a sclerosing autoimmune pancreatitis were reported to have elevated levels of serum IgG4 subclass (sIgG4). Mendes *et al*[15] reported elevated sIgG4 levels in 9% (12/127) of patients diagnosed with large duct PSC in 2006. Further retrospective studies including our own, have suggested that between 10% and 27% of patients diagnosed with PSC have an elevated sIgG4 level (PSC high sIgG4)[16-25] (Table 1).

Case series describe patients diagnosed with PSC whose liver and/or bile duct tissue is infiltrated with abundant IgG4-positive plasma cells (> 10 per high power field) either diffusely or more focal in distribution[26]. Abundant IgG4-positive plasma cells have been described in 16% to 30% of liver explants in PSC patients at different stages of the disease (Table 2)[16,26-28]. Tissue infiltration by IgG4-positive plasma cells appears to correlate with sIgG4 levels, but this is influenced by a number of factors, such as the temporal association of biopsy and serum samples, and the introduction of immunosuppressive medications for co-existing inflammatory bowel disease and/or autoimmune conditions[16,26,27].

**DIAGNOSIS OF PSC WITH HIGH IGG4 LEVELS**

A diagnosis of classical large-duct PSC is made in the presence of cholestatic liver biochemistry, characteristic bile duct changes on cholangiography, and after well-known secondary causes of cholangitis have been excluded[29]. The European Association for the Study of the Liver (EASL) Cholestatic Liver Disease Guidelines recommends that serum IgG4 levels are measured in all patients with large-duct PSC at diagnosis[29]. In those patients with an elevated sIgG4, it is important to distinguish PSC with high sIgG4 levels from IgG4-SC. If patients historically diagnosed with PSC and high sIgG4 levels are carefully categorised by clinical, radiological and histological means, between 4% and 12% may be re-classified as IgG4-SC in retrospective cohorts[16,19]. This has implications for management options, surveillance strategies and long-term prognosis.

Liver biopsy is not routinely required for the diagnosis of large-duct PSC, yet it may be indicated (1) to confirm small-duct PSC when there is clinical suspicion of cholestatic biochemistry and a normal cholangiogram; (2) to investigate evidence of autoimmune overlap with elevated liver enzymes, elevated titres of IgG and/or positive autoantibodies (> 1/40 titres); and (3) to help diagnose IgG4-SC and IgG4-related hepatopathy in those with cholestatic biochemistry and elevated liver enzymes, and abnormal cholangiogram, and with (or without) elevated sIgG4 levels. Endoscopic retrograde cholangiopancreatogram (ERCP) is reserved for patients with PSC where therapeutic intervention is required (*e.g.*, stricture dilatation or stenting), there is a high degree of suspicion for cancer (*e.g.*, stricture sampling), or where MRCP views are suboptimal/un-obtainable[30]. However, biliary biopsies obtained at either ERCP or by direct-visualisation cholangioscopy can help to distinguish a dominant stricture due to advanced PSC, IgG4-SC or cholangiocarcinoma (CCA). There are currently no guidelines to recommend routine immunostaining of liver and/or bile duct biopsy specimens for IgG4-positive cells. However, this is performed in cases with a periductal fibrosis and predominant inflammatory (plasma cell) infiltrate in our centre, and in other tertiary referral centres for PSC and IgG4-SC in Europe.

**DIFFERENTIAL DIAGNOSIS OF SCLEROSING CHOLANGITIS WITH HIGH IGG4 LEVELS**

***IgG4-SC***

IgG4-SC is the biliary manifestation of the multi-organ fibro-inflammatory IgG4-related disease (IgG4-RD). It has a male predominance, presenting in the 6th decade, usually with obstructive jaundice, weight loss and abdominal discomfort. IBD is rarely seen [< 5% of cases with autoimmune pancreatitis (AIP) type 1], compared with over 80% prevalence of UC in large-duct PSC. IgG4-SC type 2 has intra-hepatic bile duct irregularity and strictures on cholangiogram that are challenging to differentiate from large duct PSC (Figure 2)[31,32]. Co-existent AIP type 1 is present in the majority of cases (> 90%) with involvement of the distal common bile duct[8]. Extra-pancreatic organ involvement is seen in over half of cases (*e.g.*, bilateral sialadenitis, retroperitoneal fibrosis, aortitis, tubulointerstitial nephritis), which can be identified clinically and on imaging (CT chest, abdomen and pelvis, MRI of the head and neck, FDG-PET CT) if actively searched for.

Serum IgG4 levels are elevated in over 80%, serum IgE levels are elevated in 50% and a peripheral eosinophilia is present in 40% of IgG4-SC patients[33,34]. An elevated serum IgG4 level over four times the upper limit of normal has a high specificity (> 98%) to distinguish IgG4-SC from PSC, but a low sensitivity and positive predictive value[34,35]. Elevated serum IgG4 levels over two times the upper limit at diagnosis has been associated with multi-organ involvement and disease relapse in those with IgG4-SC[34]. A ratio of serum IgG1 to IgG4 of > 0.24 in those with an elevated serum IgG4 has been validated in two cohorts (Dutch and United Kingdom) to distinguish PSC high sIgG4 from IgG4-SC with high specificity (> 98%)[19,34,35]. Elevated serum IgE levels (> 125 kUL) and peripheral eosinophilia are more prominent in IgG4-SC than PSC, and historic series that document PSC patients with a peripheral eosinophilia and corticosteroid responsiveness may indeed have IgG4-SC[33,36-40]. Complement C3 and C4 levels can be low in IgG4-SC/AIP, especially in those with IgG4-related renal disease, and is rarely found in PSC high sIgG4; p-ANCA does not have a good discriminatory value[41]. More recently, a novel IgG4:IgG RNA ratio has been shown to provide excellent discrimination between IgG4-SC, PSC and CCA, regardless of the sIgG4 level, and now require real-life validation.

The histological hallmarks of IgG4-RD are a lymphoplasmacytic infiltrate with abundant IgG4-positive plasma cells, storiform pattern of fibrosis, obliterative phlebitis and variable presence of eosinophils in affected organs[42]. Liver and bile duct biopsy morphological findings can be inconclusive; ”storiform fibrosis” and ”obliterative phlebitis” is not always seen in small samples in IgG4-SC, and an ”onion-skin” fibrosis (peri-ductal concentric fibrosis) is not exclusive to PSC[43]. However, if present then they help to support the diagnosis. Abundant IgG4-positive plasma cells (> 10 per high power field in biopsy; > 50 per high power field in resection specimens) and a ratio of IgG4 to IgG-positive plasma cells > 40% in the context of classical morphological features are favourable for a diagnosis of IgG4-SC rather than PSC high IgG4[42].

Diagnostic criteria for IgG4-SC such as the Mayo HISORt for IgG4-SC (Histology, Immunology, Serology, Other organ involvement, Response to corticosteroid therapy) can be used to support a diagnosis (Table 3)[44]. A clinical scoring system has been proposed to distinguish between IgG4-SC type 2 and PSC with intra-hepatic strictures based on age, other organ involvement and beading on cholangiogram, reporting excellent discrimination (area under the receiver operating curve 0.99) between IgG4-SC and PSC in a single-centre cohort of 39 IgG4-SC and 76 PSC patients[45]. However, a mid-range score (5-6 points) prompts a diagnostic steroid trial to distinguish the two conditions, and the extent to which more advanced IgG4-SC or PSC high sIgG4 itself responds to corticosteroids is uncertain.

Based on our experience as a high-volume tertiary referral centre for PSC and IgG4-SC we have included a list of features to hep distinguish the two conditions (Table 4)[1,7,15,18,19,27,29,32,36,41,42,44-67]. Ultimately, appropriate diagnosis of PSC is crucial for optimising surveillance for disease progression and hepatic decompensation, the need for liver transplantation and malignant complications. Identification of IgG4-SC is important, as early introduction of immunosuppression improves clinical symptoms, cholestatic liver biochemistry, bile duct strictures/wall thickening on cholangiogram and may prevent advancement of disease and organ damage in both the liver and other involved organs.

***Secondary sclerosing cholangitis***

Sclerosing cholangitis can be secondary to a number of infections, vascular incidents, infiltrative conditions, immunological insults, toxins, traumatic insults and congenital disease. We have shown that serum IgG4 can be elevated in a variety of infective and inflammatory conditions[19]. It is often less than twice the upper limit of normal and falls with correction of the underlying cause[34]. Clinical history should guide the further investigation and management in this setting.

***CCA***

PSC with a dominant stricture and IgG4-SC type 1, 3 and 4 can be difficult to distinguish from a CCA. CCA usually presents with cholestasis, obstructive symptoms and a dominant stricture in the hilum, intra or extra-hepatic bile ducts with upstream dilatation. An elevated sIgG4 has been reported in up to 20% of patients with extra-hepatic CCA, although usually between one and two times the upper limit[34]. An elevated sIgG4 level over four times the upper limit has a high specificity (100%) to distinguish between IgG4-SC and CCA, but case reports of CCA arising on the background of IgG4-SC exist, and PSC is a pre-malignant condition, so sampling should always be done to rule out malignancy[6,7,29,34]. Similarly, the IgG4:IgG RNA ratio has been reported to provide excellent discrimination between IgG4-SC, PSC and CCA, but requires real-life prospective validation[35]. Ca 19-9 can be elevated in obstructive jaundice independent of the cause and is not a useful discriminator[68]. Corticosteroids may reduce the peri-tumoral inflammatory response even in CCA, and so a trial may not be discriminatory. CCA needs to be excluded in all cases as a priority, when it may be amenable to curative surgical therapy.

Abundant IgG4-positive cells have been described in resection specimens in the peri-tumoral tissue of CCA, located around the periphery of dysplastic foci[69]. Morphological assessment of tissue is required to distinguish a background of PSC or IgG4-SC, although biliary biopsies from ERCP and/or cholangioscopy are often small so can be inconclusive. Brushings are acquired for evidence of dysplasia. One small study reported that the concentration of IgG4 in bile fluid obtained at ERCP could distinguish PSC high IgG4, IgG4-SC and CCA (*n* = 54), but this has yet to be reproduced in other series[70,71].

**CLINICAL DISEASE PHENOTYPE OF PSC WITH HIGH IGG4 LEVELS**

The clinical characteristics of patients with PSC and high IgG4 levels have been described in a number of retrospective studies. The Mayo Clinic first reported that patients with PSC high sIgG4 (*n* = 12/127) had a higher level of total bilirubin and alkaline phosphatase (ALP), and a higher PSC Mayo Risk Score, than those with normal IgG4 levels[15]. A follow-on study of 285 PSC patients, carefully characterised 24 PSC high sIgG4 patients from the point of sIgG4 measurement; one-half presented with jaundice, one-fifth had pancreatic disease, all had both intra- and extra-hepatic duct strictures, and one-half had cirrhosis[17]. A study of two independent European cohorts with 345 PSC patients from Germany and Sweden similarly reported an elevated sIgG4 level was associated with a prior history of pancreatitis, combined intra- and extra hepatic duct involvement and jaundice in multi-variate analysis[22]. In a Canadian cohort of “all-comers with sclerosing cholangitis” (*n* = 101), an elevated sIgG4 was associated with elevated ALP, liver enzymes and PSC Mayo Risk Score[18]. The caveat to interpretation to these studies is that none accounted for the duration of PSC or prior/current immunosuppressive treatment for associated colitis; the latter can confound IgG4 measurements[34].

Histological assessment in liver explants of advanced PSC has demonstrated that patients with PSC and abundant IgG4 infiltration have differences in distribution and severity of biliary strictures compared with those with minimal IgG4 infiltrates. Marked hilar IgG4-positive infiltration (> 50/HPF) was associated with dominant strictures and need for biliary stenting in one study[27].

**COLITIS IN PSC AND HIGH IGG4 LEVELS**

PSC has strong links with IBD, with a reported association in Northern Europe and America of 60%-80% with UC[3,4]. The colitis of PSC-IBD has a unique clinical phenotype: a pan-colitis with prominent right sided inflammation, back-wash ileitis, rectal sparing, a quiescent and prolonged sub-clinical course.

Retrospective studies have reported a reduced frequency and more aggressive colitis in PSC with high IgG4 levels compared to normal IgG4 levels. Mendes *et al*[15] reported less frequent IBD (50% *vs* 85%)in those with PSC and high sIgG4 versus normal sIgG4 levels. Navaneethan *et al*[21] reported that those patients with PSC-UC and high sIgG4 levels were younger at PSC diagnosis, more likely to have endoscopic and histological evidence of backwash ileitis, have a flare of colitis in the preceding five-years, have a reduced colectomy-free survival and a shorter time to colectomy (5 years *vs* 12 years) after twelve-year median follow-up than those with normal sIgG4 levels.

Abundant IgG4 plasma cell infiltration in the colon (> 10 per HPF) has been reported in up to 10% (8/76) of PSC-UC patients, with an IgG4 to total IgG ratio of less than 40%[19]. We, and others, have shown that a higher IgG4 plasma cell count in the colon correlates with colitis severity in those with UC, independent of PSC diagnosis[62]. In contrast, IgG4-SC is rarely associated with an inflammatory colitis (< 5% of patients) and the colon is often infiltrated with > 50/HPF IgG4 positive plasma cells but no other morphological features.

**MALIGNANCY IN PSC AND HIGH IGG4 LEVELS**

Patients with PSC have an increased risk of hepatobiliary carcinoma, particularly CCA and gallbladder carcinoma, and in those with PSC-UC (and to a lesser extent in PSC-Crohn’s colitis) an increased risk of colorectal dysplasia and cancer[6]. Studies on PSC and high IgG4 levels have been underpowered to assess the risk of malignancy in this cohort. There were no differences in the rates of CCA, colorectal cancer and colorectal dysplasia in one small study of PSC-UC high IgG4 (*n* = 10) *vs* normal IgG4 (*n* = 40) over a ten-year follow-up period[21]. There are no studies directly addressing surveillance strategies for hepatobiliary or colorectal malignancy according to IgG4 levels in PSC, and therefore current surveillance in this cohort follows the national guidelines for PSC[72].

There is an independent association of the presence of IgG4 antibodies and malignancy; acting as a mechanism for immune evasion in malignant melanoma and abundant in the peri-tumoral tissue in pancreatic carcinoma and CCA[73,74]. Furthermore, IgG4-RD itself has been associated with an increased risk of malignancy in both retrospective and prospective cohort studies, especially within the first year of diagnosis, and often away from sites of involvement in the disease[69]. However, there is currently a lack of prospective controlled data to truly define this risk.

**THERAPEUTIC OPTIONS FOR PSC AND HIGH IGG4 LEVELS**

There is no current medical therapy that improves survival in patients diagnosed with PSC. Ursodeoxycholic acid improves liver biochemistry, but there is no evidence it alters histological progression, time to liver transplantation or mortality, whilst high doses (28-30 mg/kg) are considered toxic with an increased risk of malignancy[75,76]. Liver transplantation is currently the only option for progressive disease.

***Corticosteroids***

Several small early studies have evaluated the use of systemic and endo-biliary corticosteroid therapy in patients with PSC, with some showing evidence of clinical and biochemical improvement but concerns being raised about toxicity and disease progression[77-82]. In a case series of three patients with PSC high sIgG4 treated with high-dose corticosteroids, there was biochemical improvement but no reversal of strictures and two had rapid disease progression[28]. In a cohort study, 18 of 24 PSC high sIgG4 patients were treated with oral corticosteroids (alongside biliary stenting), and two-thirds had a biochemical response, but no reversal of strictures was reported[17]. Of concern, high rates of adverse events were reported in the steroid group (39%) including hypoglycaemia, diabetes, osteopenia and psychological disturbance. Furthermore, the group were heterogeneous, with 2 of the 18 diagnosed with AIP thus likely had IgG4-SC, and 1 of the 18 diagnosed with a CCA. The 6 who did not receive steroids had contraindications (*n* = 1) or only mild elevations of liver biochemistry (*n* = 5).

Paediatric patients who present with features of large-duct PSC on cholangiogram and/or small-duct PSC on liver biopsy will often have autoimmune features (associated with an inflammatory liver infiltrate in up to 90% of patients), which are highly responsive to corticosteroid treatment, dubbed “autoimmune sclerosing cholangitis”[83]. We have demonstrated in a small paediatric series that a quarter of these have an elevated serum IgG4 and/or infiltration of IgG4-positive plasma cells in the liver tissue[84]. It has been hypothesised that in these PSC patients with prominent plasma cell infiltrate, there is an opportunity to halt the active inflammatory element, which may benefit from steroids and possibly further immunomodulation. Adult PSC patients with autoimmune hepatitis overlap, some with inflammatory colitis, and an eosinophilia often respond favourably to steroids[72]. Those that benefit tend to be younger with a shorter disease duration, and therefore are less likely to have "burnt-out" disease.

***Immunosuppressive therapies***

Patients with PSC-IBD and/or co-existent autoimmune diseases may be on a second or third-line immunosuppressive agent. Case reports and case series have reported favourable improvements in cholestatic liver biochemistry and liver histology in patients with PSC on azathioprine, even in the absence of autoimmune hepatitis overlap[81]. Small trials have also shown improvements in liver biochemistry with tacrolimus, mycophenolate and methotrexate, and in liver histology with cyclosporine, although these have not specifically determined IgG4 level[85-88]. Concomitant use of these agents for IBD, AIH-overlap and other autoimmune disease has made it difficult to assess their effect on PSC alone per se[89].

***Biological agents***

A recent multi-centre randomised placebo-controlled phase 2b study of Simtuzimab, a monoclonal antibody directed against LOX-L2 that aims to prevent collagen cross-linking, stratified PSC patients according to serum IgG4 level. The study was negative in its primary outcome to detect mean change in hepatic collagen content. In sub-analysis, improvement in fibrosis was more common in the simtuzumab-treated groups among patients with elevated sIgG4 (> 140 mg/dL) at baseline[25]. This may be explained by the recently reported role of B cells and plasmablasts driving fibrosis in patients with IgG4-RD, which may also apply to the PSC high sIgG4 subtype[25,90]. This theory will require further exploration.

Antibodies to TNF-alpha are used in patients with IBD, and mechanistic studies have suggested that TNF-alpha may have a pathogenic role in PSC[91]. Whilst retrospective series suggested some benefits in ALP levels in PSC, a double-blind randomised controlled study showed no beneficial effect of infliximab and was stopped early due to futility, with a suggestion of harm[92]. In a retrospective PSC-IBD cohort from the Mayo treated with monoclonal antibodies (infliximab *n* = 42, adalimumab *n* = 19), only adalimumab was associated with a significant decrease in ALP at 6-8 mo, which was not sustained at 12-24 mo, and there was no radiological improvement[93]. However, to date anti-TNF response has not been stratified by IgG4 levels.

B-cell depletion with Rituximab is efficacious in patients with IgG4-SC, currently advocated for disease relapse, immunosuppressive failure and steroid-intolerance[67]. A case report in a patient with PSC and co-existent rheumatoid arthritis suggested improved liver enzyme profile, and stable cholangiographic appearances[94]. In an uncontrolled retrospective study of patients after liver transplantation, the addition of rituximab to the regimen was reported to delay PSC recurrence in the graft[95].

Case series and observational cohorts have assessed anti-integrin therapies such as vedolizumab in PSC-IBD, with conflicting results (comprehensively summarised by Lynch *et al*[96]). Whilst some patients had a fall in ALP, others had a rise in ALP and ALT levels, independent of their endoscopic/histological colitis activity response[96]. None were stratified by sIgG4 level.

***Novel therapies***

There has been a steady increase in trials of novel therapeutic agents for PSC, with the dual aims of understanding disease pathogenesis and delaying the progression of disease. There are currently multiple agents under investigation, including bile acid mimetics (nor-UDCA), Farnesoid X receptor agonists, apical sodium-dependent bile acid transporter inhibitors, antimicrobials such as vancomycin and anti-VAP1 monoclonal antibodies[97]. For the most part, small numbers of patients, inadequate characterisation, and differing endpoints have limited sub-group analysis of PSC high IgG4.

**OUTCOME IN PSC WITH HIGH IGG4 LEVELS**

The prognosis of untreated PSC is poor, with estimations of transplant-free life expectancy ranging from 12-21 years from diagnosis[98,99]. It has been proposed that disease outcome can be stratified by a number of variables, including age at presentation, serum ALP, the extent of biliary involvement, presence of cirrhosis and sIgG4 levels[48,100-102].

Early evidence suggested that PSC high sIgG4 had a worse clinical outcome than PSC normal sIgG4. Mendes *et al*[15] reported patients with PSC high IgG4 had a reduced time to liver transplantation (1.7 years *vs* 6.5 years), although overall survival was unchanged. Bjornsson *et al*[17] similarly reported PSC high IgG4 had a higher risk of progression to cirrhosis compared with those with normal levels. We also found an increased risk of progression of liver disease and requirement for liver transplantation in the group with PSC high sIgG4 levels[19]. Furthermore, in PSC patients having undergone liver transplantation, abundant IgG4 liver infiltrates were associated with a more aggressive clinical course, shorter time to transplantation, more non-cirrhotic patients at the time of transplant and an increased risk of recurrence[16]. However, none of these studies accounted for the duration of PSC and in some, failure to identify IgG4-SC may have delayed appropriate immunomodulatory treatment and favoured fibrotic progression, skewing observed results.

Larger studies have failed to demonstrate an impact of sIgG4 on outcome. In a Japanese PSC cohort (*n* = 216), high sIgG4 levels at diagnosis were associated with a higher rate of liver transplant, but this association was not preserved when controlling for confounding variables[24]. In a large European two-centre PSC cohort (*n* = 345), there was no adverse impact on outcome measures of liver transplant, liver-related death or cancer development[22]. In the randomised placebo-controlled study of Simtuzumab, the PSC high sIgG4 group did not show a more fibrotic phenotype or increased progression of cirrhosis over the 96 wk trial[25]. Other smaller retrospective studies have also failed to show a significant impact of sIgG4 levels on outcome[22,24,28]. One study showed abundant tissue IgG4-positive infiltration did not impact on outcome measures, although interpretation of these results is limited as low numbers of IgG4-positive cells were considered as abundant[27].

**PATHOGENIC MECHANISMS IN PSC HIGH IGG4**

PSC is considered to be an immune-mediated disease. Several mechanisms have been proposed, involving dysregulation of immune signalling, increased permeability of the bowel wall allowing exposure of toxins to the liver, and damage from toxic bile acids (for a comprehensive review see Karlsen *et al*[2]). An intriguing question is how and if PSC high IgG4 differs in its pathogenesis from IgG4-SC and PSC with normal IgG4 levels (Figure 3).

**GENETIC ASSOCIATIONS**

Various risk loci in genome-wide associations (GWAS) and Immunochip studies in PSC have been identified, particularly representing the major histocompatibility complex (MHC) on chromosome 6. Human leukocyte antigen (HLA) DRB1\*0301, DRB1\*1301 and DRB1\*1501, associated with autoimmune disease, have been identified as associated with PSC, although no single susceptibility gene is known[2,54-57]. A recent genetic analysis of HLA haplotypes in PSC highlighted different associations in patients with PSC with high and normal sIgG4 levels (*n* = 263)[58]. HLA-B\*08 allele (strongest PSC risk factor) was less prevalent in patients with PSC high sIgG4 (> 1.35 g/L and > 2.0 g/L), whereas HLA-B\*07 and DRB1\*15 (on the same conserved haplotype, AH7.1) were more prevalent in PSC high sIgG4 (IgG4 > 2.0 g/L)[58]. This finding was replicated in Swedish and US cohorts[58]. A recent GWAS in 857 IgG4-RD patients in Japan and over 2000 healthy controls identified the HLA-DRB1 and FCGR2B regions as susceptibility loci for IgG4-RD[103]. Asian studies have reported higher frequencies of the DRB1\*0405-DQB1\*0401 haplotype in Japanese patients with AIP compared to healthy individuals and chronic calcifying pancreatitis[59].In the United Kingdom, we have demonstrated an increased frequency of HLA-DRB1\*0301-DQB1\*0201 in a multi-centre cohort of IgG4-SC/AIP patients compared to healthy individuals[60]. Thus, whilst there are overlaps in HLA class II DRB1 associations in PSC (high and normal sIgG4) and IgG4-SC, certain haplotypes are more prominent in the PSC high IgG4 subtype (HLA-B\*07 and DRB1\*15).

**IGG4 ANTIBODIES**

IgG4 is the least prevalent of the four IgG subclasses in health, representing 3%–6% of total IgG. Physiological IgG4 responses can be induced by repeat or high antigen exposure and are associated with tolerance induction such as in immunotherapy. IgG4 production is driven predominantly by T helper-2 cytokines (IL4 and IL13) which induce IgG4 and IgE antibodies, T-regulatory cytokine (IL10) and T-follicular/peripheral helper cytokine (IL21) that shifts this balance towards IgG4, known as the “modified Th2 response”[104,105]. The glycosylation pattern of an antibody can influence its cellular functions and pathogenicity, including complement and Fc receptor binding. We demonstrated that glycosylation of the Fab arms of IgG4 antibodies is increased compared to that of other IgG subclasses[106]. We showed altered IgG4 Fab and IgG1 and IgG4 Fc antibody glycosylation in IgG4-SC and PSC high sIgG4; with disease-specific enhancement of IgG4-specific Fab sialylation, reduction in IgG1-specific Fc bisection and recovery with steroid treatment in IgG4-SC, and reduced IgG1-specific sialylation in those with PSC[106]. Ultimately, the prominence of IgG4 antibodies in some patients with PSC and IgG4-SC may result in differential response to antigen exposure and downstream Fc-effector functions compared with those with normal IgG4 levels.

**CHRONIC ANTIGEN EXPOSURE**

IgG4 can protect against IgE-mediated allergic reactions, and it has been speculated that the chronically raised IgG4 levels may represent chronic activation of this protective mechanism in the presence of long-term antigen exposure[107]. We described chronic exposure to environmental antigens, such as occupational exposures in “blue collar workers”, more frequently in those with IgG4-SC compared with all PSC patients, and in PSC high sIgG4 compared with normal sIgG4 levels[108]. We also demonstrated a polyclonal IgG4 response to diverse antigens in IgG4-SC and PSC high sIgG4 compared with PSC normal IgG4 and heathy controls, supporting expansion of pre-existing IgG4-switched B cells in both conditions[109].

**IMMUNE ENVIRONMENT**

Chemokines recruit inflammatory cells to affected tissues, and differences in chemokine and cytokine expression have been demonstrated in the liver of patients with IgG4-SC, PSC high and normal sIgG4 levels. In IgG4-SC and PSC high IgG4 there is over-expression of CCL1 (highly expressed in peri-biliary epithelium), CCR8 (important in recruitment of Th2 and T-regulatory cells), and cytokines IL4 and IL10, compared with PSC normal IgG4[110]. CCL1 chemotactic factor was positive in infiltrating lymphocytes in PSC high IgG4 compared with peri-biliary glands, pancreatic duct epithelium, and vascular endothelial cells involved in obliterative phlebitis affected in IgG4-SC[110]. Thus, elevated IgG4 levels in PSC (and IgG4-SC) may represent a sustained immunoreaction to unidentified antigen(s), and favour a type-2 cytokine response, derived from Th-2 and T-regulatory cells.

**CONCLUSION**

PSC patients with high IgG4 levels appear to have a distinct clinical phenotype, HLA associations, cytokine and chemokine profiles, and post-translational antibody modifications compared to PSC patients with normal IgG4 levels. It is important to distinguish PSC high IgG4 from IgG4-SC, other causes of secondary sclerosing cholangitis and CCA - all of which can have elevated IgG4 levels. Corticosteroids may improve biochemical parameters in all conditions, however there are concerns regarding steroid toxicity and disease progression in a sub-group of patients with PSC high IgG4 and more advanced cirrhosis. Currently, lack of robust data, an absence of well-designed prospective studies, and the aforementioned safety concerns limit acceptability and use of immunosuppressants in the context of PSC high IgG4. This may be more applicable in paediatric variants with “autoimmune sclerosing cholangitis” and overlap with an autoimmune hepatitis with predominant IgG4-positive plasma cells. Moving forward, we believe it will be important to continue to incorporate the IgG4 level into prospective clinical trial design of novel therapies in PSC.

**REFERENCES**

1 **Singh S**, Talwalkar JA. Primary sclerosing cholangitis: diagnosis, prognosis, and management. *Clin Gastroenterol Hepatol* 2013; **11**: 898-907 [PMID: 23454027 DOI: 10.1016/j.cgh.2013.02.016]

2 **Karlsen TH**, Franke A, Melum E, Kaser A, Hov JR, Balschun T, Lie BA, Bergquist A, Schramm C, Weismüller TJ, Gotthardt D, Rust C, Philipp EE, Fritz T, Henckaerts L, Weersma RK, Stokkers P, Ponsioen CY, Wijmenga C, Sterneck M, Nothnagel M, Hampe J, Teufel A, Runz H, Rosenstiel P, Stiehl A, Vermeire S, Beuers U, Manns MP, Schrumpf E, Boberg KM, Schreiber S. Genome-wide association analysis in primary sclerosing cholangitis. *Gastroenterology* 2010; **138**: 1102-1111 [PMID: 19944697 DOI: 10.1053/j.gastro.2009.11.046]

3 **Boonstra K**, de Vries EM, van Geloven N, van Erpecum KJ, Spanier M, Poen AC, van Nieuwkerk CM, Witteman BJ, Tuynman HA, Naber AH, Kingma PJ, Beuers U, Ponsioen CY; Epi PSC PBC Study Group. Risk factors for primary sclerosing cholangitis. *Liver Int* 2016; **36**: 84-91 [PMID: 26077553 DOI: 10.1111/liv.12894]

4 **Boonstra K**, van Erpecum KJ, van Nieuwkerk KM, Drenth JP, Poen AC, Witteman BJ, Tuynman HA, Beuers U, Ponsioen CY. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. *Inflamm Bowel Dis* 2012; **18**: 2270-2276 [PMID: 22407885 DOI: 10.1002/ibd.22938]

5 **Floreani A**, Rizzotto ER, Ferrara F, Carderi I, Caroli D, Blasone L, Baldo V. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. *Am J Gastroenterol* 2005; **100**: 1516-1522 [PMID: 15984974 DOI: 10.1111/j.1572-0241.2005.41841.x]

6 **Williamson KD**, Chapman RW. Primary sclerosing cholangitis: a clinical update. *Br Med Bull* 2015; **114**: 53-64 [PMID: 25981516 DOI: 10.1093/bmb/ldv019]

7 **Chapman R**, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ; American Association for the Study of Liver Diseases. Diagnosis and management of primary sclerosing cholangitis. *Hepatology* 2010; **51**: 660-678 [PMID: 20101749 DOI: 10.1002/hep.23294]

8 **Culver EL**, Chapman RW. Systematic review: management options for primary sclerosing cholangitis and its variant forms - IgG4-associated cholangitis and overlap with autoimmune hepatitis. *Aliment Pharmacol Ther* 2011; **33**: 1273-1291 [PMID: 21501198 DOI: 10.1111/j.1365-2036.2011.04658.x]

9 **Erkelens GW**, Vleggaar FP, Lesterhuis W, van Buuren HR, van der Werf SD. Sclerosing pancreato-cholangitis responsive to steroid therapy. *Lancet* 1999; **354**: 43-44 [PMID: 10406367]

10 **Ichimura T**, Kondo S, Ambo Y, Hirano S, Ohmi M, Okushiba S, Morikawa T, Shimizu M, Katoh H. Primary sclerosing cholangitis associated with autoimmune pancreatitis. *Hepatogastroenterology* 2002; **49**: 1221-1224 [PMID: 12239909]

11 **Kawaguchi K**, Koike M, Tsuruta K, Okamoto A, Tabata I, Fujita N. Lymphoplasmacytic sclerosing pancreatitis with cholangitis: a variant of primary sclerosing cholangitis extensively involving pancreas. *Hum Pathol* 1991; **22**: 387-395 [PMID: 2050373]

12 **Kazumori H**, Ashizawa N, Moriyama N, Arima N, Hirakawa K, Adachi K, Watanabe M, Kinoshita Y, Tamura K. Primary sclerosing pancreatitis and cholangitis. *Int J Pancreatol* 1998; **24**: 123-127 [PMID: 9816546 DOI: 10.1007/BF02788570]

13 **Nakazawa T**, Ohara H, Yamada T, Ando H, Sano H, Kajino S, Hashimoto T, Nakamura S, Ando T, Nomura T, Joh T, Itoh M. Atypical primary sclerosing cholangitis cases associated with unusual pancreatitis. *Hepatogastroenterology* 2001; **48**: 625-630 [PMID: 11462890]

14 **Kojima E**, Kimura K, Noda Y, Kobayashi G, Itoh K, Fujita N. Autoimmune pancreatitis and multiple bile duct strictures treated effectively with steroid. *J Gastroenterol* 2003; **38**: 603-607 [PMID: 12856677]

15 **Mendes FD**, Jorgensen R, Keach J, Katzmann JA, Smyrk T, Donlinger J, Chari S, Lindor KD. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. *Am J Gastroenterol* 2006; **101**: 2070-2075 [PMID: 16879434 DOI: 10.1111/j.1572-0241.2006.00772.x]

16 **Zhang L**, Lewis JT, Abraham SC, Smyrk TC, Leung S, Chari ST, Poterucha JJ, Rosen CB, Lohse CM, Katzmann JA, Wu TT. IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis. *Am J Surg Pathol* 2010; **34**: 88-94 [PMID: 20035148]

17 **Björnsson E**, Chari S, Silveira M, Gossard A, Takahashi N, Smyrk T, Lindor K. Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. *Am J Ther* 2011; **18**: 198-205 [PMID: 20228674 DOI: 10.1097/MJT.0b013e3181c9dac6]

18 **Alswat K**, Al-Harthy N, Mazrani W, Alshumrani G, Jhaveri K, Hirschfield GM. The spectrum of sclerosing cholangitis and the relevance of IgG4 elevations in routine practice. *Am J Gastroenterol* 2012; **107**: 56-63 [PMID: 22068666 DOI: 10.1038/ajg.2011.375]

19 **Culver EL,** Williamson KD, Halliday J, Bateman AC, Sadler R, Barnes E, Chapman RW. Elevated serum and tissue IgG4 in PSC are associated with a worse clinical outcome. *Hepatology* 2012; **56**: 1131A-1131A

20 **Parhizkar B**, Mohammad Alizadeh AH, Asadzadeh Aghdaee H, Malekpour H, Entezari AH. Primary sclerosing cholangitis associated with elevated immunoglobulin-g4: a preliminary study. *ISRN Gastroenterol* 2012; **2012**: 325743 [PMID: 22988518 DOI: 10.5402/2012/325743]

21 **Navaneethan U**, Venkatesh PG, Choudhary M, Shen B, Kiran RP. Elevated immunoglobulin G4 level is associated with reduced colectomy-free survival in patients with primary sclerosing cholangitis and ulcerative colitis. *J Crohns Colitis* 2013; **7**: e35-e41 [PMID: 22554774 DOI: 10.1016/j.crohns.2012.04.006]

22 **Benito de Valle M**, Müller T, Björnsson E, Otten M, Volkmann M, Guckelberger O, Wiedenmann B, Sadik R, Schott E, Andersson M, Berg T, Lindkvist B. The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis. *Dig Liver Dis* 2014; **46**: 903-908 [PMID: 25091876 DOI: 10.1016/j.dld.2014.06.010]

23 **Taghavi SA**, Majd SK, Sianati M, Sepehrimanesh M. Prevalence of IgG-4-associated cholangiopathy based on serum IgG-4 levels in patients with primary sclerosing cholangitis and its relationship with inflammatory bowel disease. *Turk J Gastroenterol* 2016; **27**: 547-552 [PMID: 27852547 DOI: 10.5152/tjg.2016.16344]

24 **Tanaka A**, Tazuma S, Nakazawa T, Isayama H, Tsuyuguchi T, Inui K, Takikawa H. No negative impact of serum IgG4 levels on clinical outcome in 435 patients with primary sclerosing cholangitis from Japan. *J Hepatobiliary Pancreat Sci* 2017; **24**: 217-225 [PMID: 28103424 DOI: 10.1002/jhbp.432]

25 **Muir AJ**, Levy C, Janssen HLA, Montano-Loza AJ, Shiffman ML, Caldwell S, Luketic V, Ding D, Jia C, McColgan BJ, McHutchison JG, Mani Subramanian G, Myers RP, Manns M, Chapman R, Afdhal NH, Goodman Z, Eksteen B, Bowlus CL; GS-US-321-0102 Investigators. Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. *Hepatology* 2019; **69**: 684-698 [PMID: 30153359 DOI: 10.1002/hep.30237]

26 **Zen Y**, Quaglia A, Portmann B. Immunoglobulin G4-positive plasma cell infiltration in explanted livers for primary sclerosing cholangitis. *Histopathology* 2011; **58**: 414-422 [PMID: 21348891 DOI: 10.1111/j.1365-2559.2011.03763.x]

27 **Fischer S**, Trivedi PJ, Ward S, Greig PD, Therapondos G, Hirschfield GM. Frequency and significance of IgG4 immunohistochemical staining in liver explants from patients with primary sclerosing cholangitis. *Int J Exp Pathol* 2014; **95**: 209-215 [PMID: 24750423 DOI: 10.1111/iep.12076]

28 **Koyabu M**, Uchida K, Fukata N, Kusuda T, Ikeura T, Sakaguchi Y, Yoshida K, Shimatani M, Fukui T, Matsushita M, Uemura Y, Kaibori M, Takaoka M, Nishio A, Okazaki K. Primary sclerosing cholangitis with elevated serum IgG4 levels and/or infiltration of abundant IgG4-positive plasma cells. *J Gastroenterol* 2010; **45**: 122-129 [PMID: 19760481 DOI: 10.1007/s00535-009-0130-y]

29 **European Association for the Study of the Liver**. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. *J Hepatol* 2009; **51**: 237-267 [PMID: 19501929 DOI: 10.1016/j.jhep.2009.04.009]

30 **Bangarulingam SY**, Gossard AA, Petersen BT, Ott BJ, Lindor KD. Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. *Am J Gastroenterol* 2009; **104**: 855-860 [PMID: 19259076 DOI: 10.1038/ajg.2008.161]

31 **Kalaitzakis E**, Levy M, Kamisawa T, Johnson GJ, Baron TH, Topazian MD, Takahashi N, Kanno A, Okazaki K, Egawa N, Uchida K, Sheikh K, Amin Z, Shimosegawa T, Sandanayake NS, Church NI, Chapman MH, Pereira SP, Chari S, Webster GJ. Endoscopic retrograde cholangiography does not reliably distinguish IgG4-associated cholangitis from primary sclerosing cholangitis or cholangiocarcinoma. *Clin Gastroenterol Hepatol* 2011; **9**: 800-803.e2 [PMID: 21699807 DOI: 10.1016/j.cgh.2011.05.019]

32 **Goodchild G**, Pereira SP, Webster G. Immunoglobulin G4-related sclerosing cholangitis. *Korean J Intern Med* 2018; **33**: 841-850 [PMID: 30045615 DOI: 10.3904/kjim.2018.018]

33 **Culver EL**, Sadler R, Bateman AC, Makuch M, Cargill T, Ferry B, Aalberse R, Barnes E, Rispens T. Increases in IgE, Eosinophils, and Mast Cells Can be Used in Diagnosis and to Predict Relapse of IgG4-Related Disease. *Clin Gastroenterol Hepatol* 2017; **15**: 1444-1452.e6 [PMID: 28223204 DOI: 10.1016/j.cgh.2017.02.007]

34 **Culver EL**, Sadler R, Simpson D, Cargill T, Makuch M, Bateman AC, Ellis AJ, Collier J, Chapman RW, Klenerman P, Barnes E, Ferry B. Elevated Serum IgG4 Levels in Diagnosis, Treatment Response, Organ Involvement, and Relapse in a Prospective IgG4-Related Disease UK Cohort. *Am J Gastroenterol* 2016; **111**: 733-743 [PMID: 27091321 DOI: 10.1038/ajg.2016.40]

35 **Boonstra K**, Culver EL, de Buy Wenniger LM, van Heerde MJ, van Erpecum KJ, Poen AC, van Nieuwkerk KM, Spanier BW, Witteman BJ, Tuynman HA, van Geloven N, van Buuren H, Chapman RW, Barnes E, Beuers U, Ponsioen CY. Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. *Hepatology* 2014; **59**: 1954-1963 [PMID: 24375491 DOI: 10.1002/hep.26977]

36 **Tabibian JH**, Enders F, Imam MH, Kolar G, Lindor KD, Talwalkar JA. Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis. *Ann Hepatol* 2014; **13**: 384-389 [PMID: 24756015]

37 **Hirano K**, Tada M, Mizuno S, Isayama H, Takahara N, Nagano R, Hamada T, Miyabayashi K, Ito Y, Mohri D, Kawakubo K, Sasaki T, Kogure H, Yamamoto N, Sasahira N, Yamashiki N, Sugawara Y, Kokudo N, Toda N, Koike K. Lower incidence of biliary carcinoma in patients with primary sclerosing cholangitis and high serum levels of immunoglobulin E. *Clin Gastroenterol Hepatol* 2012; **10**: 79-83 [PMID: 21963955 DOI: 10.1016/j.cgh.2011.09.015]

38 **Neeman A**, Kadish U. Marked eosinophilia in a patient with primary sclerosing cholangitis. *Am J Med* 1987; **83**: 378-379 [PMID: 3618646]

39 **Watanabe H**, Ohira H, Kuroda M, Takagi T, Ishikawa H, Nishimaki T, Kasukawa R, Takahashi K. Primary sclerosing cholangitis with marked eosinophilic infiltration in the liver. *J Gastroenterol* 1995; **30**: 524-528 [PMID: 7550866]

40 **Ichikawa N**, Taniguchi A, Akama H, Ishiguro H, Kurihara T, Terai C, Hara M, Kashiwazaki S. Sclerosing cholangitis associated with hypereosinophilic syndrome. *Intern Med* 1997; **36**: 561-564 [PMID: 9260773]

41 **Evans RDR**, Cargill T, Goodchild G, Oliveira B, Rodriguez-Justo M, Pepper R, Connolly J, Salama A, Webster G, Barnes E, Culver EL. Clinical Manifestations and Long-term Outcomes of IgG4-Related Kidney and Retroperitoneal Involvement in a United Kingdom IgG4-Related Disease Cohort. *Kidney Int Rep* 2019; **4**: 48-58 [PMID: 30596168 DOI: 10.1016/j.ekir.2018.08.011]

42 **Deshpande V**, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, Klöppel G, Heathcote JG, Khosroshahi A, Ferry JA, Aalberse RC, Bloch DB, Brugge WR, Bateman AC, Carruthers MN, Chari ST, Cheuk W, Cornell LD, Fernandez-Del Castillo C, Forcione DG, Hamilos DL, Kamisawa T, Kasashima S, Kawa S, Kawano M, Lauwers GY, Masaki Y, Nakanuma Y, Notohara K, Okazaki K, Ryu JK, Saeki T, Sahani DV, Smyrk TC, Stone JR, Takahira M, Webster GJ, Yamamoto M, Zamboni G, Umehara H, Stone JH. Consensus statement on the pathology of IgG4-related disease. *Mod Pathol* 2012; **25**: 1181-1192 [PMID: 22596100 DOI: 10.1038/modpathol.2012.72]

43 **Desmet VJ**. Histopathology of chronic cholestasis and adult ductopenic syndrome. *Clin Liver Dis* 1998; **2**: 249-264, viii [PMID: 15560031]

44 **Ghazale A**, Chari ST, Zhang L, Smyrk TC, Takahashi N, Levy MJ, Topazian MD, Clain JE, Pearson RK, Petersen BT, Vege SS, Lindor K, Farnell MB. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. *Gastroenterology* 2008; **134**: 706-715 [PMID: 18222442 DOI: 10.1053/j.gastro.2007.12.009]

45 **Moon SH**, Kim MH, Lee JK, Baek S, Woo YS, Cho DH, Oh D, Song TJ, Park DH, Lee SS, Seo DW, Lee SK. Development of a scoring system for differentiating IgG4-related sclerosing cholangitis from primary sclerosing cholangitis. *J Gastroenterol* 2017; **52**: 483-493 [PMID: 27470434 DOI: 10.1007/s00535-016-1246-5]

46 **Webster GJ**, Pereira SP, Chapman RW. Autoimmune pancreatitis/IgG4-associated cholangitis and primary sclerosing cholangitis--overlapping or separate diseases? *J Hepatol* 2009; **51**: 398-402 [PMID: 19505739 DOI: 10.1016/j.jhep.2009.04.010]

47 **Huggett MT**, Culver EL, Kumar M, Hurst JM, Rodriguez-Justo M, Chapman MH, Johnson GJ, Pereira SP, Chapman RW, Webster GJM, Barnes E. Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort. *Am J Gastroenterol* 2014; **109**: 1675-1683 [PMID: 25155229 DOI: 10.1038/ajg.2014.223]

48 **Tischendorf JJ**, Hecker H, Krüger M, Manns MP, Meier PN. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. *Am J Gastroenterol* 2007; **102**: 107-114 [PMID: 17037993 DOI: 10.1111/j.1572-0241.2006.00872.x]

49 **Hamano H**, Arakura N, Muraki T, Ozaki Y, Kiyosawa K, Kawa S. Prevalence and distribution of extrapancreatic lesions complicating autoimmune pancreatitis. *J Gastroenterol* 2006; **41**: 1197-1205 [PMID: 17287899 DOI: 10.1007/s00535-006-1908-9]

50 **Kaplan GG**, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. *Am J Gastroenterol* 2007; **102**: 1042-1049 [PMID: 17313496 DOI: 10.1111/j.1572-0241.2007.01103.x]

51 **Navaneethan U**, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. *Inflamm Bowel Dis* 2010; **16**: 1598-1619 [PMID: 20198712 DOI: 10.1002/ibd.21219]

52 **Nakazawa T**, Ohara H, Sano H, Aoki S, Kobayashi S, Okamoto T, Imai H, Nomura T, Joh T, Itoh M. Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis. *Gastrointest Endosc* 2004; **60**: 937-944 [PMID: 15605009]

53 **Stinton LM**, Bentow C, Mahler M, Norman GL, Eksteen B, Mason AL, Kaplan GG, Lindkvist B, Hirschfield GM, Milkiewicz P, Cheung A, Janssen HL, Fritzler MJ. PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC). *PLoS One* 2014; **9**: e112877 [PMID: 25397578 DOI: 10.1371/journal.pone.0112877]

54 **Ellinghaus D**, Folseraas T, Holm K, Ellinghaus E, Melum E, Balschun T, Laerdahl JK, Shiryaev A, Gotthardt DN, Weismüller TJ, Schramm C, Wittig M, Bergquist A, Björnsson E, Marschall HU, Vatn M, Teufel A, Rust C, Gieger C, Wichmann HE, Runz H, Sterneck M, Rupp C, Braun F, Weersma RK, Wijmenga C, Ponsioen CY, Mathew CG, Rutgeerts P, Vermeire S, Schrumpf E, Hov JR, Manns MP, Boberg KM, Schreiber S, Franke A, Karlsen TH. Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. *Hepatology* 2013; **58**: 1074-1083 [PMID: 22821403 DOI: 10.1002/hep.25977]

55 **Liu JZ**, Hov JR, Folseraas T, Ellinghaus E, Rushbrook SM, Doncheva NT, Andreassen OA, Weersma RK, Weismüller TJ, Eksteen B, Invernizzi P, Hirschfield GM, Gotthardt DN, Pares A, Ellinghaus D, Shah T, Juran BD, Milkiewicz P, Rust C, Schramm C, Müller T, Srivastava B, Dalekos G, Nöthen MM, Herms S, Winkelmann J, Mitrovic M, Braun F, Ponsioen CY, Croucher PJ, Sterneck M, Teufel A, Mason AL, Saarela J, Leppa V, Dorfman R, Alvaro D, Floreani A, Onengut-Gumuscu S, Rich SS, Thompson WK, Schork AJ, Næss S, Thomsen I, Mayr G, König IR, Hveem K, Cleynen I, Gutierrez-Achury J, Ricaño-Ponce I, van Heel D, Björnsson E, Sandford RN, Durie PR, Melum E, Vatn MH, Silverberg MS, Duerr RH, Padyukov L, Brand S, Sans M, Annese V, Achkar JP, Boberg KM, Marschall HU, Chazouillères O, Bowlus CL, Wijmenga C, Schrumpf E, Vermeire S, Albrecht M; UK-PSCSC Consortium, Rioux JD, Alexander G, Bergquist A, Cho J, Schreiber S, Manns MP, Färkkilä M, Dale AM, Chapman RW, Lazaridis KN; International PSC Study Group, Franke A, Anderson CA, Karlsen TH; International IBD Genetics Consortium. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. *Nat Genet* 2013; **45**: 670-675 [PMID: 23603763 DOI: 10.1038/ng.2616]

56 **Folseraas T**, Melum E, Rausch P, Juran BD, Ellinghaus E, Shiryaev A, Laerdahl JK, Ellinghaus D, Schramm C, Weismüller TJ, Gotthardt DN, Hov JR, Clausen OP, Weersma RK, Janse M, Boberg KM, Björnsson E, Marschall HU, Cleynen I, Rosenstiel P, Holm K, Teufel A, Rust C, Gieger C, Wichmann HE, Bergquist A, Ryu E, Ponsioen CY, Runz H, Sterneck M, Vermeire S, Beuers U, Wijmenga C, Schrumpf E, Manns MP, Lazaridis KN, Schreiber S, Baines JF, Franke A, Karlsen TH. Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. *J Hepatol* 2012; **57**: 366-375 [PMID: 22521342 DOI: 10.1016/j.jhep.2012.03.031]

57 **Melum E**, Franke A, Schramm C, Weismüller TJ, Gotthardt DN, Offner FA, Juran BD, Laerdahl JK, Labi V, Björnsson E, Weersma RK, Henckaerts L, Teufel A, Rust C, Ellinghaus E, Balschun T, Boberg KM, Ellinghaus D, Bergquist A, Sauer P, Ryu E, Hov JR, Wedemeyer J, Lindkvist B, Wittig M, Porte RJ, Holm K, Gieger C, Wichmann HE, Stokkers P, Ponsioen CY, Runz H, Stiehl A, Wijmenga C, Sterneck M, Vermeire S, Beuers U, Villunger A, Schrumpf E, Lazaridis KN, Manns MP, Schreiber S, Karlsen TH. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. *Nat Genet* 2011; **43**: 17-19 [PMID: 21151127 DOI: 10.1038/ng.728]

58 **Berntsen NL**, Klingenberg O, Juran BD, Benito de Valle M, Lindkvist B, Lazaridis KN, Boberg KM, Karlsen TH, Hov JR. Association Between HLA Haplotypes and Increased Serum Levels of IgG4 in Patients With Primary Sclerosing Cholangitis. *Gastroenterology* 2015; **148**: 924-927.e2 [PMID: 25655558 DOI: 10.1053/j.gastro.2015.01.041]

59 **Kawa S**, Ota M, Yoshizawa K, Horiuchi A, Hamano H, Ochi Y, Nakayama K, Tokutake Y, Katsuyama Y, Saito S, Hasebe O, Kiyosawa K. HLA DRB10405-DQB10401 haplotype is associated with autoimmune pancreatitis in the Japanese population. *Gastroenterology* 2002; **122**: 1264-1269 [PMID: 11984513]

60 **Culver EL,** Hurst JM, Cargill T, Joshi D, Nayar M, Huggett MT, Oppong K, Savic S, Bateman AC, Chapman RW, Webster GJM, Barnes E. Human Leucocyte Antigen Associations in IgG4-related disease and Primary sclerosing cholangitis stratified by IgG4 levels, in a multicenter UK cohort. *J Hepatol* 2016; **64**: S646-S646 [DOI: https://doi.org/10.1016/S0168-8278(16)01205-8]

61 **Kim JH**, Byun JH, Kim SY, Lee SS, Kim HJ, Kim MH, Lee MG. Sclerosing cholangitis with autoimmune pancreatitis versus primary sclerosing cholangitis: comparison on endoscopic retrograde cholangiography, MR cholangiography, CT, and MRI. *Acta Radiol* 2013; **54**: 601-607 [PMID: 23528564 DOI: 10.1177/0284185113481018]

62 **Orlicza K,** Culver EL, Bateman A, Sadler R, Barnes E, Chapman RW, Travis SPL. IgG4-positive plasma cells in the colon of patients with ulcerative colitis are markers of endoscopic and histological disease activity. *JCC* 2013; **7**: S101 [DOI: 10.1016/S1873-9946(13)60250-0]

63 **Berstad AE**, Aabakken L, Smith HJ, Aasen S, Boberg KM, Schrumpf E. Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. *Clin Gastroenterol Hepatol* 2006; **4**: 514-520 [PMID: 16616358 DOI: 10.1016/j.cgh.2005.10.007]

64 **Chari ST**, Smyrk TC, Levy MJ, Topazian MD, Takahashi N, Zhang L, Clain JE, Pearson RK, Petersen BT, Vege SS, Farnell MB. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. *Clin Gastroenterol Hepatol* 2006; **4**: 1010-6; quiz 934 [PMID: 16843735 DOI: 10.1016/j.cgh.2006.05.017]

65 **Culver EL**, Barnes E. IgG4-related sclerosing cholangitis. *Clin Liver Dis (Hoboken)* 2017; **10**: 9-16 [PMID: 30992751]

66 **Cebe KM**, Swanson PE, Upton MP, Westerhoff M. Increased IgG4+ cells in duodenal biopsies are not specific for autoimmune pancreatitis. *Am J Clin Pathol* 2013; **139**: 323-329 [PMID: 23429368 DOI: 10.1309/AJCPT00NHQHXAHDS]

67 **Carruthers MN**, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, Deshpande V, Smyrk TC, Chari S, Stone JH. Rituximab for IgG4-related disease: a prospective, open-label trial. *Ann Rheum Dis* 2015; **74**: 1171-1177 [PMID: 25667206 DOI: 10.1136/annrheumdis-2014-206605]

68 **Marrelli D**, Caruso S, Pedrazzani C, Neri A, Fernandes E, Marini M, Pinto E, Roviello F. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. *Am J Surg* 2009; **198**: 333-339 [PMID: 19375064 DOI: 10.1016/j.amjsurg.2008.12.031]

69 **Kimura Y**, Harada K, Nakanuma Y. Pathologic significance of immunoglobulin G4-positive plasma cells in extrahepatic cholangiocarcinoma. *Hum Pathol* 2012; **43**: 2149-2156 [PMID: 22647350 DOI: 10.1016/j.humpath.2012.03.001]

70 **Navaneethan U**, Gutierrez NG, Jegadeesan R, Venkatesh PG, Poptic E, Sanaka MR, Vargo JJ, Parsi MA. IgG4 Levels in Bile for Distinguishing IgG4-Associated Cholangiopathy from Other Biliary Disorders: A Single Blinded Pilot Study. *Clin Endosc* 2014; **47**: 555-559 [PMID: 25505722 DOI: 10.5946/ce.2014.47.6.555]

71 **Vosskuhl K**, Negm AA, Framke T, Weismüller T, Manns MP, Wedemeyer H, Plentz RR, Wedemeyer J, Lankisch TO. Measurement of IgG4 in bile: a new approach for the diagnosis of IgG4-associated cholangiopathy. *Endoscopy* 2012; **44**: 48-52 [PMID: 22198775 DOI: 10.1055/s-0030-1256872]

72 **Chapman MH**, Thorburn D, Hirschfield GM, Webster GGJ, Rushbrook SM, Alexander G, Collier J, Dyson JK, Jones DE, Patanwala I, Thain C, Walmsley M, Pereira SP. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. *Gut* 2019; **68**: 1356-1378 [PMID: 31154395 DOI: 10.1136/gutjnl-2018-317993]

73 **Karagiannis P**, Gilbert AE, Josephs DH, Ali N, Dodev T, Saul L, Correa I, Roberts L, Beddowes E, Koers A, Hobbs C, Ferreira S, Geh JL, Healy C, Harries M, Acland KM, Blower PJ, Mitchell T, Fear DJ, Spicer JF, Lacy KE, Nestle FO, Karagiannis SN. IgG4 subclass antibodies impair antitumor immunity in melanoma. *J Clin Invest* 2013; **123**: 1457-1474 [PMID: 23454746 DOI: 10.1172/JCI65579]

74 **Liu Q**, Niu Z, Li Y, Wang M, Pan B, Lu Z, Liao Q, Zhao Y. Immunoglobulin G4 (IgG4)-positive plasma cell infiltration is associated with the clinicopathologic traits and prognosis of pancreatic cancer after curative resection. *Cancer Immunol Immunother* 2016; **65**: 931-940 [PMID: 27271551 DOI: 10.1007/s00262-016-1853-2]

75 **Lindor KD**. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. *N Engl J Med* 1997; **336**: 691-695 [PMID: 9041099 DOI: 10.1056/NEJM199703063361003]

76 **Olsson R**, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, Bell H, Gangsøy-Kristiansen M, Matre J, Rydning A, Wikman O, Danielsson A, Sandberg-Gertzén H, Ung KA, Eriksson A, Lööf L, Prytz H, Marschall HU, Broomé U. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. *Gastroenterology* 2005; **129**: 1464-1472 [PMID: 16285948 DOI: 10.1053/j.gastro.2005.08.017]

77 **Angulo P**, Batts KP, Jorgensen RA, LaRusso NA, Lindor KD. Oral budesonide in the treatment of primary sclerosing cholangitis. *Am J Gastroenterol* 2000; **95**: 2333-2337 [PMID: 11007238 DOI: 10.1111/j.1572-0241.2000.02323.x]

78 **Boberg KM**, Egeland T, Schrumpf E. Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. *Scand J Gastroenterol* 2003; **38**: 991-995 [PMID: 14531538]

79 **Lindor KD**, Wiesner RH, Colwell LJ, Steiner B, Beaver S, LaRusso NF. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. *Am J Gastroenterol* 1991; **86**: 57-61 [PMID: 1986556]

80 **Parkes M**, Booth JC, Pillai G, Mee AS. Do steroids help jaundice caused by primary sclerosing cholangitis? *J Clin Gastroenterol* 2001; **33**: 319-322 [PMID: 11588548]

81 **Schramm C**, Schirmacher P, Helmreich-Becker I, Gerken G, zum Büschenfelde KH, Lohse AW. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series. *Ann Intern Med* 1999; **131**: 943-946 [PMID: 10610645]

82 **van Hoogstraten HJ**, Vleggaar FP, Boland GJ, van Steenbergen W, Griffioen P, Hop WC, van Hattum J, van Berge Henegouwen GP, Schalm SW, van Buuren HR. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. *Am J Gastroenterol* 2000; **95**: 2015-2022 [PMID: 10950051 DOI: 10.1111/j.1572-0241.2000.02267.x]

83 **el-Shabrawi M**, Wilkinson ML, Portmann B, Mieli-Vergani G, Chong SK, Williams R, Mowat AP. Primary sclerosing cholangitis in childhood. *Gastroenterology* 1987; **92**: 1226-1235 [PMID: 3493939]

84 **Culver EL,** Rodriguez A, Bateman A, Collier J, Chapman RW, Barnes E. IgG4-plasma cell infiltrate in the liver and colon of children with PSC. *J Hepatol* 2012; **56**: S543

85 **Wiesner RH**, Grambsch PM, Dickson ER, Ludwig J, MacCarty RL, Hunter EB, Fleming TR, Fisher LD, Beaver SJ, LaRusso NF. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. *Hepatology* 1989; **10**: 430-436 [PMID: 2777204]

86 **Talwalkar JA**, Gossard AA, Keach JC, Jorgensen RA, Petz JL, Lindor RN. Tacrolimus for the treatment of primary sclerosing cholangitis. *Liver Int* 2007; **27**: 451-453 [PMID: 17403184 DOI: 10.1111/j.1478-3231.2007.01441.x]

87 **Knox TA**, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. *Gastroenterology* 1994; **106**: 494-499 [PMID: 8299916]

88 **Talwalkar JA**, Angulo P, Keach JC, Petz JL, Jorgensen RA, Lindor KD. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. *Am J Gastroenterol* 2005; **100**: 308-312 [PMID: 15667487 DOI: 10.1111/j.1572-0241.2005.40484.x]

89 **Gregorio GV**, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, Mieli-Vergani G. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. *Hepatology* 2001; **33**: 544-553 [PMID: 11230733 DOI: 10.1053/jhep.2001.22131]

90 **Della-Torre E**, Rigamonti E, Perugino C, Baghai-Sain S, Sun N, Kaneko N, Maehara T, Rovati L, Ponzoni M, Milani R, Lanzillotta M, Mahajan V, Mattoo H, Molineris I, Deshpande V, Stone JH, Falconi M, Manfredi AA, Pillai S. B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease. *J Allergy Clin Immunol* 2020; **145**: 968-981.e14 [PMID: 31319101 DOI: 10.1016/j.jaci.2019.07.004]

91 **Aoki CA**, Bowlus CL, Gershwin ME. The immunobiology of primary sclerosing cholangitis. *Autoimmun Rev* 2005; **4**: 137-143 [PMID: 15823499 DOI: 10.1016/j.autrev.2004.09.003]

92 **Hommes DW**, Erkelens W, Ponsioen C, Stokkers P, Rauws E, van der Spek M, ten Kate F, van Deventer SJ. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. *J Clin Gastroenterol* 2008; **42**: 522-526 [PMID: 18344886 DOI: 10.1097/MCG.0b013e3181662426]

93 **Tse CS**, Loftus EV Jr, Raffals LE, Gossard AA, Lightner AL. Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease. *Aliment Pharmacol Ther* 2018; **48**: 190-195 [PMID: 29808485 DOI: 10.1111/apt.14829]

94 **Franceschet I**, Cazzagon N, Del Ross T, D'Incà R, Buja A, Floreani A. Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options. *Eur J Gastroenterol Hepatol* 2016; **28**: 508-513 [PMID: 26872110 DOI: 10.1097/MEG.0000000000000596]

95 **Yamada Y**, Hoshino K, Fuchimoto Y, Matsubara K, Hibi T, Yagi H, Abe Y, Shinoda M, Kitago M, Obara H, Yagi T, Okajima H, Kaido T, Uemoto S, Suzuki T, Kubota K, Yoshizumi T, Maehara Y, Inomata Y, Kitagawa Y, Egawa H, Kuroda T. Rituximab Induction to Prevent the Recurrence of PSC After Liver Transplantation-The Lessons Learned From ABO-Incompatible Living Donor Liver Transplantation. *Transplant Direct* 2018; **4**: e342 [PMID: 29464203 DOI: 10.1097/TXD.0000000000000760]

96 **Lynch KD**, Keshav S, Chapman RW. The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. *Curr Hepatol Rep* 2019; **18**: 115-126 [PMID: 31008013 DOI: 10.1007/s11901-019-00456-2]

97 **Ponsioen CY**, Chapman RW, Chazouillères O, Hirschfield GM, Karlsen TH, Lohse AW, Pinzani M, Schrumpf E, Trauner M, Gores GJ. Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. *Hepatology* 2016; **63**: 1357-1367 [PMID: 26418478 DOI: 10.1002/hep.28256]

98 **Broomé U**, Olsson R, Lööf L, Bodemar G, Hultcrantz R, Danielsson A, Prytz H, Sandberg-Gertzén H, Wallerstedt S, Lindberg G. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. *Gut* 1996; **38**: 610-615 [PMID: 8707097]

99 **Boonstra K**, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BW, Poen AC, van Nieuwkerk KM, Drenth JP, Witteman BJ, Tuynman HA, Naber AH, Kingma PJ, van Buuren HR, van Hoek B, Vleggaar FP, van Geloven N, Beuers U, Ponsioen CY; EpiPSCPBC Study Group. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. *Hepatology* 2013; **58**: 2045-2055 [PMID: 23775876 DOI: 10.1002/hep.26565]

100 **Farrant JM**, Hayllar KM, Wilkinson ML, Karani J, Portmann BC, Westaby D, Williams R. Natural history and prognostic variables in primary sclerosing cholangitis. *Gastroenterology* 1991; **100**: 1710-1717 [PMID: 1850376]

101 **Al Mamari S**, Djordjevic J, Halliday JS, Chapman RW. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. *J Hepatol* 2013; **58**: 329-334 [PMID: 23085647 DOI: 10.1016/j.jhep.2012.10.013]

102 **Trivedi PJ**, Corpechot C, Pares A, Hirschfield GM. Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists. *Hepatology* 2016; **63**: 644-659 [PMID: 26290473 DOI: 10.1002/hep.28128]

103 **Terao C,** Ota M, Iwasaki, T, Shiokawa M, Kawaguchi S, Kuriyama K, Kawaguchi T, Kodama Y, Yamaguchi I, Uchida K, Higasa K, Yamamoto M, MD, Kubota K, Yazumi S, Hirano K, MD, Masaki Y, Maguchi H, Origuchi T, Matsui S, Nakazawa T, Shiomi H, Kamisawa T, Hasebe O, Iwasaki E, Inui K, Tanaka Y, Ohshima K, Akamizu T, Nakamura S, Nakamura S, Saeki T, Umehara H, Shimosegawa T, Mizuno N, Kawano M, Azumi A, Takahashi H, Mimori T, Kamatani Y, Okazaki K, Chiba T, Kawa S, Matsuda F on behalf of the Japanese IgG4-Related Disease Working Consortium. IgG4-related disease in the Japanese population:a genome-wide association study. *Lancet Rheumatol* 2019; **1**: e14-e22 [doi: 10.1016/S2665-9913(19)30006-2]

104 **Cargill T**, Makuch M, Sadler R, Lighaam LC, Peters R, van Ham M, Klenerman P, Bateman A, Rispens T, Barnes E, Culver EL. Activated T-Follicular Helper 2 Cells Are Associated With Disease Activity in IgG4-Related Sclerosing Cholangitis and Pancreatitis. *Clin Transl Gastroenterol* 2019; Online ahead of print [PMID: 31045595 DOI: 10.14309/ctg.0000000000000020]

105 **Cargill T**, Barnes E, Culver EL. Expansion of a Novel Subset of PD1+CXCR5-CD4+ T Peripheral Helper Cells in IgG4-Related Disease. *Clin Transl Gastroenterol* 2020; **11**: e00111 [PMID: 31977453]

106 **Culver EL**, van de Bovenkamp FS, Derksen NIL, Koers J, Cargill T, Barnes E, de Neef LA, Koeleman CAM, Aalberse RC, Wuhrer M, Rispens T. Unique patterns of glycosylation in immunoglobulin subclass G4-related disease and primary sclerosing cholangitis. *J Gastroenterol Hepatol* 2019; **34**: 1878-1886 [PMID: 30345709 DOI: 10.1111/jgh.14512]

107 **Umehara H**, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, Matsui S, Sumida T, Mimori T, Tanaka Y, Tsubota K, Yoshino T, Kawa S, Suzuki R, Takegami T, Tomosugi N, Kurose N, Ishigaki Y, Azumi A, Kojima M, Nakamura S, Inoue D; Research Program for Intractable Disease by Ministry of Health, Labor and Welfare (MHLW) Japan G4 team. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. *Mod Rheumatol* 2012; **22**: 1-14 [PMID: 21881964 DOI: 10.1007/s10165-011-0508-6]

108 **de Buy Wenniger LJ**, Culver EL, Beuers U. Exposure to occupational antigens might predispose to IgG4-related disease. *Hepatology* 2014; **60**: 1453-1454 [PMID: 24407836 DOI: 10.1002/hep.26999]

109 **Culver EL**, Vermeulen E, Makuch M, van Leeuwen A, Sadler R, Cargill T, Klenerman P, Aalberse RC, van Ham SM, Barnes E, Rispens T. Increased IgG4 responses to multiple food and animal antigens indicate a polyclonal expansion and differentiation of pre-existing B cells in IgG4-related disease. *Ann Rheum Dis* 2015; **74**: 944-947 [PMID: 25646372 DOI: 10.1136/annrheumdis-2014-206405]

110 **Zen Y**, Liberal R, Nakanuma Y, Heaton N, Portmann B. Possible involvement of CCL1-CCR8 interaction in lymphocytic recruitment in IgG4-related sclerosing cholangitis. *J Hepatol* 2013; **59**: 1059-1064 [PMID: 23811304 DOI: 10.1016/j.jhep.2013.06.016]

**Footnotes**

**Conflict-of-interest statement:** There are no commercial or financial conflicts of interest related to this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding Author's Membership(s) in Professional Societies:** European Association for the Study of the Liver; British Association for the Study of the Liver; British Society of Gastroenterology; and Royal College of Physicians.

**Peer-review started:** December 23, 2019

**First decision:** March 23, 2020

**Article in press:** June 5, 2020

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United Kingdom

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B, B

Grade C (Good): C, C, C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Balaban YH, Cerwenka H, Chiu KW, Ikura Y, Slomiany BL, Tomizawa M, Vorobjova T **S-Editor:** Gong ZM **L-Editor: E-Editor:** Ma YJ

**Figure Legends**



**Figure 1 Decision tree for literature research strategy.** PSC: Primary sclerosing cholangitis.



**A B**

**Figure 2 IgG4-related sclerosing cholangitis type 2 (primary sclerosing cholangitis-like).** A 58-year old female with cholestatic liver biochemistry, elevated serum IgG4 and IgE, and peripheral blood eosinophilia.A: Magnetic resonance cholangiopancreatography (MRCP) demonstrates common bile duct stricture (CBD) (arrow), intrahepatic duct irregularity and strictures (arrows) and beading (arrows). The liver biochemistry, serum IgG4 level, common bile duct and intrahepatic duct strictures improved after 12 wk of corticosteroid therapy. Endoscopic retrograde cholangiopancreatography and brushings of the CBD stricture were negative for dysplasia. B: MRCP demonstrates new right intra-hepatic duct stricture (arrow) and improvement of CBD stricture (arrow) one year later. Azathioprine (1.5 mg/kg) started to reduce further risk of disease relapse. CBD: Common bile duct.

****

**Figure 3 Pathogenic factors driving the phenotype of primary sclerosing cholangitis with an increased IgG4 level.** HLA: Human leukocyte antigen; PSC: Primary sclerosing cholangitis.

**Table 1 Studies evaluating serum IgG4 in primary sclerosing cholangitis patients**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Study design** | **Location** | **No. of PSC patients** | **Percentage (%) with high serum IgG4** | **Key findings in PSC high IgG4** |
| Mendes *et al*[15], 2006  | Retrospective case control study | United States | 127 | 9% | Higher bilirubin, ALP and PSC Mayo risk score, lower IBD and shorter time to liver transplantation |
| Zhang *et al*[16], 2010 | Retrospective cohort study | United States | 81 | 22% | Serum IgG4 levels correlated with tissue IgG4 infiltration in liver explants. |
| Bjornsson *et al*[17], 2011 | Retrospective cohort study with prospective follow-up of PSC high serum IgG4 | Sweden | 285 | 12% | Presented with jaundice, both intra and extra hepatic strictures, and pancreatic disorders. 50% had cirrhosis.Biochemical response to steroids (*n* = 12/18).Steroid side effects (39%) |
| Alswat *et al*[18], 2012 | Retrospective cohort study | Canada | 101 | 22% | Male gender, High ALP, High PSC Mayo Risk Score, Pancreatitis, Previous biliary intervention, Abnormal pancreatic imaging. |
| Culver *et al*[19], 2012 | Retrospective cohort study with prospective follow-up of PSC high and normal IgG4 | United Kingdom | 194 | 14% | 14% of 186 patients. Worse clinical outcome including liver transplantation and progression of liver disease. |
| Parhizkar *et al*[20], 2013 | Retrospective cross-sectional study | Iran | 34 | 26.5% | Male and non-smokers.No outcome differences. |
| Navaneethan *et al*[21], 2013  | Retrospective cohort study | United States | 50 | 20% | Elevated serum IgG4 associated with reduced colectomy-free survival in PSC-UCShorter time to colectomy from diagnosis of PSC, median time 5 yr (high IgG4) v 12 yr (normal IgG4) *P* = 0.01 |
| Benito de Valle *et al*[22], 2014 | Retrospective multi-centre (2) cohort study | Sweden and Germany | 345 | 10% | History of pancreatitis combined intrahepatic and extra hepatic biliary involvement, and jaundice.No increased risk of liver transplantation, death or CCA. |
| Taghavi *et al*[23], 2016 | Retrospective cohort study | Iran | 73 | 16% | Higher prevalence of ascites.No clinical outcome differences |
| Tanaka *et al*[24], 2017 | Questionnaire‐based, multi‐centre, retrospective cohort study | Japan | 216 | 12.5% | Overall mortality and liver transplantation-free survival rate was not different |
| Muir *et al*[25], 2018 | Phase 2b, dose-ranging, randomized, double-blind, and placebo-controlled study | Northern United States and Europe (61 sites) | 234 | 15% | No difference in fibrosis and progression to cirrhosis in groups stratified by IgG4 level at recruitment |

ALP: Alkaline phosphatase; IBD: Inflammatory bowel disease; PSC: Primary sclerosing cholangitis; UC: Ulcerative colitis.

**Table 2 Studies evaluating abundant tissue IgG4-positive plasma cells in primary sclerosing cholangitis patients**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Study design** | **Location** | **PSC patients" number** | **Percentage (%) with abundant tissue IgG4** | **Key findings in PSC high IgG4** |
| Koyabu *et al*[28], 2010 | Case series | Japan | 3 | Biopsy.2/3 (> 10/HPF) | Infiltration of IgG4-positive plasma cells in portal area of the liver.No improvement in strictures after steroid therapy. |
| Zhang *et al*[16], 2010 | Retrospective cohort study with paired serum and liver explant tissue | United States | 98 | Liver explants.23% (> 10 /HPF) | Shorter time to transplant. More non-cirrhotic at transplant. Higher likelihood of recurrence. |
| Zen *et al*[26], 2011 | Retrospective cohort study | United Kingdom | 41 | 29% (> 10/HPF)5% (> 100 /HPF) | Bile duct erosion and xanthogranulomatous reaction. |
| Fischer *et al*[27], 2014 | Retrospective cohort study | Canada | 122 | 16% (> 50/HPF) | Marked hilar staining significantly associated with dominant biliary strictures and need for biliary stenting.No differences in outcome. |

HPF: High power field; PSC: Primary sclerosing cholangitis.

**Table 3 HISORt Criteria for IgG4-related sclerosing cholangitis (Adapted from references[32,44])**

|  |  |
| --- | --- |
| Histology (Criterion H) | Lymphoplasmacytic infiltrate with > 10 IgG4+ cells per high‐power field within and around bile ducts; obliterative phlebitis; storiform fibrosis |
| Imaging (Criterion I) | Strictures of the biliary tree including intrahepatic ducts, proximal extra-hepatic ducts, intra-pancreatic ducts; fleeting and migrating biliary strictures. |
| Serology (Criterion S) | Raised serum IgG4 levels (> 1.35 g/L) |
| Organ involvement (Criterion O) | Extra-biliary manifestations consistent with IgG4-RD, such as: pancreas (focal pancreatic mass/enlargement without pancreatic duct dilatation, multiple pancreatic masses, focal pancreatic duct stricture without upstream dilatation, pancreatic atrophy); retroperitoneal fibrosis; kidney (single or multiple parenchymal low‐attenuation lesions: round, wedge‐shaped, or diffuse patchy); salivary or lacrimal gland (enlargement).  |
| Response to treatment (Criterion R) | Normalisation of liver enzymes and at least partial stricture resolution after steroid treatment.  |

Definite IgG4-SC: Patient meets criterion H or Criterion S with Criterion I; Probable IgG4-SC: Patient meets 2 of the following criteria: Criterion S, Criterion O, partially meets criterion H, partially meets criterion I. Patients with probable diagnosis can proceed to trial of corticosteroids. If they then meet criterion R, then the diagnosis becomes definite. IgG4-RD: IgG4-related disease; IgG4-SC: IgG4-related sclerosing cholangitis.

**Table 4 Features to distinguish primary sclerosing cholangitis with high serum IgG4 from IgG4-related sclerosing cholangitis**

|  |  |  |
| --- | --- | --- |
|  | **PSC with high IgG4** | **IgG4-SC** |
| Demographics and history | Gender distribution[46] | Males > Females (7:1) | Males > Females (1.5:1) |
| Age distribution[1,44] | < 50 yr | > 60 yr |
| Presentation[47-50] | Cholestatic liver biochemistry in patients with IBDSymptoms of pruritus and fatigue. Jaundice rare (< 5%) | Symptoms of obstructive jaundice, weight loss, abdominal painMasses or dysfunction of other organs if systemic disease |
| Relationship to IBD[4,51] | Association with IBD, the majority with UC (80%) | Rare association with colitis (5%).Must be in the context of systemic disease |
| Pancreatic involvement[52] | Atypical to have co-existent pancreatic disease (< 5%), usually in the context of iatrogenic (azathioprine-induced) acute pancreatitis | Association with autoimmune pancreatitis in the majority (90%-95%) |
| Laboratory investigations | Autoantibodies[53] | PR3-ANCA present in 40% | No specific autoantibodies |
| Serology[18] | Serum IgG4 < equal to 2 × ULN | Serum value of > 5.6 g/LSerum IgG4:IgG1 ration of > 0.24 has 95% specificity for IgG4-SCIgG4: IgG RNA ratioSerum IgE raised in 50% IgG4-SC |
| HLA-typing[2,42,54-60] | DRB1\*0301, DRB1\*1301 and DRB1\*1501 in PSCHLA-B\*08 less prevalent in PSC high sIgG4HLA-B\*07 and DRB1\*15 more prevalent in PSC high sIgG4 | HLA DRB1\*0405-DQB1\*0401 and HLA-DRB1\*0301-DQB1\*0201 associated with AIP |
| Radiology and endoscopy | Cholangiography findings[52,61] | Short band-like strictures, Beaded or prune-tree appearanceContinuous bile duct involvementCBD wall thickness > 2.5 mm | Long strictures, pre-stenotic bile duct dilation, hilar, intrahepatic and distal CBD involvement, often “skip” lesions |
| Cross sectional imaging[36,41,42,47,62,63] | MRCP | Cross-sectional imaging *e.g.,* CT chest abdomen and pelvis or PET-CT to look for masses or fibrosis in other organs |
| Histology | Hepatobiliary[27,64,65] | (1) Peri-portal sclerosis(2)"Onion-skin" fibrosis | (1) Lymphoplasmacytic infiltrate with abundant IgG4-positive plasma cells(2) "Storiform" fibrosis,(3) Obliterative phlebitis,(4) Eosinophils, variable |
| Other organs[42,62,66] | IBD – colitis | Often concurrent masses in other organs *e.g.,* salivary gland, pancreaticImmunostaining of tissue with IgG4 and IgG; ratio of IgG4:IgG > 40% and IgG4 > 10/HPF |
| Criteria | Diagnostic Criteria[32,44] | CholestasisAbnormal CholangiogramHigh sIgG4High tIgG4 if biopsy | HISORt for IgG4-SC (Table 3): histology, imaging, serology, organ involvement, response to steroids |
| Moon *et al* Scoring system[45] | Score of 0-4 PSCScore 5-6 points, suggest diagnostic steroid trial. | Score of 7-9 |
|  | Sub-types of disease[5,29,32,50] | Large-duct PSC (classical)Small-duct PSCPSC-AIH overlap | Type 1 IgG4-SC: distal CBD and pancreasType 2 IgG4-SC: CHDType 3 IgG4-SC: CHD with left-right IHDType 4 IgG4-SC: hilar |
| Malignancy | Cancer[7,47] | Increased risk of hepatobiliary malignancy (CCA and gall bladder) and colorectal carcinoma in those with IBD | Increased risk of any malignancy |
| Management | Treatment[7,29,67] | High-dose corticosteroid trial with biochemical and imaging response can be considered but high-risk side effect.UDCA use controversial: EASL guidelines recommend low-dose (13-15 mg/kg) for chemoprevention role.High-dose (28-30 mg/kg) UDCA toxic in PSC.3. Liver transplantation | If serology and radiology supportive, with or without histology, and malignancy has been excluded, consider high dose steroid trial for 4 wk *e.g.,* prednisolone 40 mg 2 wk then 30 mg 2 wk and reassess biochemistry and imaging for evidence of response1. Corticosteroids first-line (high dose 40 mg 2 wk and taper) with good response in the majority (> 95% with AIP and 2/3 with IgG4-SC)2. Immunomodulators second line, often azathioprine3. Rituximab for refractory or relapsing disease, and in those with steroid-intolerance |
| Prognosis  | Outcomes[15,19] | Possible rapid progression of disease compared to PSC patients with normal serum IgG4 levels | Excellent response if treated with immunosuppression early before development of fibrotic strictures |

AIP: Autoimmune pancreatitis; ALP: Alkaline phosphatase; CBD: Common bile duct; CCA: Cholangiocarcinom; EASL: European Association for the Study of the Liver; IBD: Inflammatory bowel disease; PSC: Primary sclerosing cholangitis; UC: Ulcerative colitis; IgG4-SC: IgG4-related sclerosing cholangitis; MRCP: Magnetic resonance cholangiopancreatography; HLA: Human leukocyte antigen; UDCA: Urseodeoxycholic acid.